# Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L

Source: https://onco.cc/trials/nct06253663/  
OnCo record `nct06253663` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Brexucabtagene autoleucel, Cyclophosphamide, Fludarabine in mantle cell lymphoma, run by Kite, A Gilead Company, active and no longer recruiting.

## Summary

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia is a phase 2 interventional study registered as NCT06253663 by Kite, A Gilead Company, with 25 participants enrolled, started 2024-03-18 and due to reach its primary completion in 2027-07. Interventions recorded: KTE-X19, Cyclophosphamide, Fludarabine. Conditions listed: Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06253663
- Phase: 2
- Setting: A Phase 2 Multicenter Study Evaluating the Safety and the Efficacy of KTE-X19 in Adult Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Sponsor: Kite, A Gilead Company
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT06253663: https://clinicaltrials.gov/study/NCT06253663

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Brexucabtagene autoleucel](https://onco.cc/drugs/brexucabtagene-autoleucel/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct06253663.json